RU2606128C2 - Соединения для применения в лечении мукозита - Google Patents

Соединения для применения в лечении мукозита Download PDF

Info

Publication number
RU2606128C2
RU2606128C2 RU2013155678A RU2013155678A RU2606128C2 RU 2606128 C2 RU2606128 C2 RU 2606128C2 RU 2013155678 A RU2013155678 A RU 2013155678A RU 2013155678 A RU2013155678 A RU 2013155678A RU 2606128 C2 RU2606128 C2 RU 2606128C2
Authority
RU
Russia
Prior art keywords
independently
alkyl
group
independently represents
groups
Prior art date
Application number
RU2013155678A
Other languages
English (en)
Russian (ru)
Other versions
RU2013155678A (ru
Inventor
Ричард У. СКОТТ
Божена КОРЧАК
Original Assignee
Селлсьютикс Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Селлсьютикс Корпорейшн filed Critical Селлсьютикс Корпорейшн
Publication of RU2013155678A publication Critical patent/RU2013155678A/ru
Application granted granted Critical
Publication of RU2606128C2 publication Critical patent/RU2606128C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
RU2013155678A 2011-05-16 2012-05-15 Соединения для применения в лечении мукозита RU2606128C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161486455P 2011-05-16 2011-05-16
US61/486,455 2011-05-16
PCT/US2012/037895 WO2012158672A2 (en) 2011-05-16 2012-05-15 Compounds for use in treatment of mucositis

Publications (2)

Publication Number Publication Date
RU2013155678A RU2013155678A (ru) 2015-06-27
RU2606128C2 true RU2606128C2 (ru) 2017-01-10

Family

ID=47175383

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013155678A RU2606128C2 (ru) 2011-05-16 2012-05-15 Соединения для применения в лечении мукозита

Country Status (14)

Country Link
US (6) US8802683B2 (enExample)
EP (1) EP2709619B1 (enExample)
JP (1) JP5833745B2 (enExample)
KR (1) KR102012164B1 (enExample)
CN (1) CN103957710B (enExample)
AU (1) AU2012255935B2 (enExample)
CA (1) CA2836099C (enExample)
DK (1) DK2709619T3 (enExample)
IL (1) IL229381B (enExample)
MX (1) MX2013013330A (enExample)
RU (1) RU2606128C2 (enExample)
TW (1) TWI520951B (enExample)
WO (1) WO2012158672A2 (enExample)
ZA (1) ZA201308541B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090092574A1 (en) 2006-12-29 2009-04-09 Scott Richard W Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
TWI520951B (zh) * 2011-05-16 2016-02-11 塞爾西優蒂克斯公司 用於治療粘膜炎的化合物
HK1210437A1 (en) * 2012-12-18 2016-04-22 Jawaharlal Nehru Centre For Advanced Scientific Research Antimicrobial compounds, their synthesis and applications thereof
CA2901576C (en) * 2013-02-15 2021-03-23 Technische Universitat Berlin Albicidin derivatives, their use and synthesis
SG11201506359UA (en) 2013-03-15 2015-09-29 Genzyme Corp Amine functional polyamides
JP6047203B2 (ja) * 2015-02-20 2016-12-21 セルセウティックス コーポレイション 消化管の炎症性疾患の予防および／または治療のための宿主防御タンパク質（ｈｄｐ）模倣薬
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
JP7050165B2 (ja) 2018-02-26 2022-04-07 ギリアード サイエンシーズ， インコーポレイテッド Ｈｂｖ複製阻害剤としての置換ピロリジン化合物
US11771694B2 (en) 2020-06-05 2023-10-03 Innovation Pharmaceuticals Inc. Arylamide compounds for treatment and prevention of viral infections
JP2024532086A (ja) 2021-08-30 2024-09-05 ユニケム ラボラトリーズ リミテッド 炎症性疾患の処置のためのタンパク質組成物
CN114890982A (zh) * 2022-05-16 2022-08-12 内蒙古大学 一种季铵盐修饰的二苯并噻吩亚砜衍生物的制备方法
CN117402075A (zh) * 2023-10-17 2024-01-16 厦门大学深圳研究院 一种具有特异性抗肿瘤活性的可见光响应的人工h+/ci-离子通道的制备

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025326A (en) * 1995-07-07 2000-02-15 Intrabiotics Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of oral mucositis
WO2004082634A2 (en) * 2003-03-17 2004-09-30 The Trustees Of The University Of Pennsylvania Facially amphiphilic polymers and oligomers and uses thereof
WO2006122162A2 (en) * 2005-05-10 2006-11-16 The University Of Chicago Use of peptides derived from the growth factor amp-18 for the treatment of mucositis
WO2008083256A2 (en) * 2006-12-29 2008-07-10 Polymedix, Inc. Ophthalmic and otic compositions of facially amphiphilic polymers and oligomers and uses thereof
RU2540077C2 (ru) * 2008-10-27 2015-01-27 Селлсьютикс Корпорейшн Синтетические миметики иммунной защиты и их применение

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3496179A (en) 1967-10-11 1970-02-17 Pfizer & Co C 2-amino-3,4-dihydroquinazolines
CA2128612C (en) 1992-01-23 1999-06-15 Mamoru Tomita Antimicrobial agents and method for treating products therewith
US5994306A (en) * 1995-11-22 1999-11-30 Intrabiotics Pharmaceuticals, Inc. Fine-tuned protegrins
JP3090125B2 (ja) 1997-08-26 2000-09-18 千寿製薬株式会社 ソフトコンタクトレンズ用の眼科用組成物、ソフトコンタクトレンズの濡れ増強方法およびテルペノイドの吸着抑制方法
JP2003523927A (ja) 1998-08-20 2003-08-12 ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル ジカチオンジベンゾフランおよびジベンゾチオフェン化合物並びにその使用法
US20040152664A1 (en) 1998-09-02 2004-08-05 Allergan, Inc. Prednisolone compositions
US6440964B1 (en) 1998-09-30 2002-08-27 Alcon Manufacturing, Ltd. Compositions and methods for treating ophthalmic and otic infections
US6482799B1 (en) 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
JP2001261674A (ja) 2000-03-22 2001-09-26 Mitsui Chemicals Inc ベンゾチオフェン誘導体およびそれを有効成分として含有する核内レセプター作動薬
FR2813080B1 (fr) 2000-08-17 2002-11-29 Stago Diagnostica Peptides anti-heparine
CN1263463C (zh) 2000-11-08 2006-07-12 生物概念实验室 含有过氧化物源和阳离子型聚合物防腐剂的改进的眼科和隐型眼镜用溶液
WO2002056895A2 (en) * 2001-01-18 2002-07-25 Genzyme Corporation Ionene polymers and their use in treating mucositis
CN1522148A (zh) 2001-03-08 2004-08-18 ��Ϧ�������ݴ�ѧ���»� 作为抗感染药的表面两亲聚合物
US7629317B2 (en) 2001-03-29 2009-12-08 The University Of Chicago Control of growth and repair of gastro-intestinal tissues by gastrokines and inhibitors
AR034372A1 (es) 2001-06-08 2004-02-18 Novartis Ag Composiciones farmaceuticas
AU2002341566A1 (en) * 2001-08-16 2003-04-01 Mucosal Therapeutics, Inc. Treatment and prevention of mucositis in cancer patients
WO2003100701A1 (en) 2002-05-28 2003-12-04 The Trustees Of The University Of Pennsylvania Methods, systems, and computer program products for computational analysis and design of amphiphilic polymers
EP1513622A4 (en) 2002-06-13 2005-09-14 Univ Pennsylvania METHODS, SYSTEMS AND COMPUTER PROGRAM PRODUCTS FOR STIMULATING BIOMEMBRANES USING ROUGH GRAIN MODELS
WO2004046109A2 (en) * 2002-11-19 2004-06-03 Genzyme Corporation Ionene oligomers and polymers
WO2004082643A2 (fr) 2003-03-20 2004-09-30 Shiseido International France Composition cosmetique
US20040202687A1 (en) 2003-04-14 2004-10-14 Babu M.K. Manoj Ciprofloxacin formulations and methods of making and using the same
US20050059639A1 (en) 2003-09-11 2005-03-17 Wei Edward T. Ophthalmic compositions and method for treating eye discomfort and pain
US20050065091A1 (en) 2003-09-18 2005-03-24 Gholam Peyman Stabilized ocular solutions
EP2468711A3 (en) 2004-01-23 2012-09-19 The Trustees Of The University Of Pennsylvania Facially amphiphilic polyaryl and polarylalkynyl polymers and oligomers and uses thereof
WO2005123660A2 (en) * 2004-06-15 2005-12-29 Polymedix, Inc. Polycationic compounds and uses thereof
JP5027659B2 (ja) 2004-07-23 2012-09-19 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 抗菌コポリマーおよびその使用
CA2599205A1 (en) 2005-02-25 2006-09-08 The Trustees Of The University Of Pennsylvania Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in methods of treating cancer
DK1704860T3 (da) * 2005-03-24 2011-02-07 Rottapharm Spa Benzamidinderivater til behandling og forebyggelse af mucositis
US7951829B2 (en) * 2006-05-03 2011-05-31 Janssen Pharmaceutica Nv Benzimidazole modulators of VR1
JP2008137978A (ja) 2006-12-05 2008-06-19 Canon Inc カルバゾール誘導体及びこれを用いた有機発光素子
US20100297257A1 (en) 2007-11-09 2010-11-25 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs) Anticoagulant antagonist and hemophillia procoagulant
CA2732572A1 (en) 2008-07-28 2010-02-04 Polymedix, Inc. Anti-malarial compounds
WO2010068700A1 (en) * 2008-12-10 2010-06-17 Polymedix, Inc. Antimicrobial molecules for treating multi-drug resistant and extensively drug resistant strains of mycobacterium
UA110323C2 (en) * 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
BR112012016570A2 (pt) * 2010-01-07 2016-04-05 Polymedix Inc composto, composição farmacêutica, método para antagonizar a heparina não fracionada, heparina de peso molecular baixo, ou derivado de heparina /heparina de peso molecular baixo, e, uso do composto
TW201208677A (en) * 2010-08-21 2012-03-01 Polymedix Inc Facially amphiphilic compounds, compositions, and uses thereof in treating cancer
TWI520951B (zh) * 2011-05-16 2016-02-11 塞爾西優蒂克斯公司 用於治療粘膜炎的化合物
EP2790510A4 (en) * 2011-12-13 2015-11-25 Cellceutix Corp CYCLIC COMPOUNDS AND PROCESS FOR THEIR PREPARATION AND USE
MX2014008763A (es) * 2012-01-18 2015-04-13 Cellceutix Corp Compuestos y metodos para tratar infecciones por candidosis y aspergillus.
WO2014093225A2 (en) * 2012-12-10 2014-06-19 Cellceutix Corporation Polycyclic compounds and methods of making and using the same
WO2014093231A2 (en) * 2012-12-10 2014-06-19 Cellceutix Corporation Hybrid compounds and methods of making and using the same
MX363678B (es) * 2013-05-28 2019-03-29 Morphochem Aktiengesellschaft Fuer Komb Torische Chemie Terapia de combinación que comprende oxazolidinona-quinolonas para usarse en el tratamiento de infecciones bacterianas.
JP6047203B2 (ja) * 2015-02-20 2016-12-21 セルセウティックス コーポレイション 消化管の炎症性疾患の予防および／または治療のための宿主防御タンパク質（ｈｄｐ）模倣薬

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025326A (en) * 1995-07-07 2000-02-15 Intrabiotics Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of oral mucositis
WO2004082634A2 (en) * 2003-03-17 2004-09-30 The Trustees Of The University Of Pennsylvania Facially amphiphilic polymers and oligomers and uses thereof
WO2006122162A2 (en) * 2005-05-10 2006-11-16 The University Of Chicago Use of peptides derived from the growth factor amp-18 for the treatment of mucositis
WO2008083256A2 (en) * 2006-12-29 2008-07-10 Polymedix, Inc. Ophthalmic and otic compositions of facially amphiphilic polymers and oligomers and uses thereof
RU2540077C2 (ru) * 2008-10-27 2015-01-27 Селлсьютикс Корпорейшн Синтетические миметики иммунной защиты и их применение

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DONNELLY ET AL.: "Antimicrobial therapy to prevent or treat oral mucositis", LANCET INFECTIOUS DISEASES, ELSEVIER LTD, US, 2003, vol. 3, no. 7, pages 405-412. *
DONNELLY ET AL.: "Antimicrobial therapy to prevent or treat oral mucositis", LANCET INFECTIOUS DISEASES, ELSEVIER LTD, US, 2003, vol. 3, no. 7, pages 405-412. LOURY D J ET AL.: "Effect of local application of the antimicrobial peptide IB-367 on the incidence and severity of oral mucositis in hamsters", ORAL SURGERY, ORAL MEDICINE, ORAL PATHOLOGY, ORAL RADIOLOGY AND ENDODONTICS, MOSBY-YEAR BOOK, ST. LOUIS, MO, US, 1999, vol. 87, no. 5, pages 544-551. *
LOURY D J ET AL.: "Effect of local application of the antimicrobial peptide IB-367 on the incidence and severity of oral mucositis in hamsters", ORAL SURGERY, ORAL MEDICINE, ORAL PATHOLOGY, ORAL RADIOLOGY AND ENDODONTICS, MOSBY-YEAR BOOK, ST. LOUIS, MO, US, 1999, vol. 87, no. 5, pages 544-551. *

Also Published As

Publication number Publication date
IL229381A0 (en) 2014-01-30
US20120295922A1 (en) 2012-11-22
CA2836099A1 (en) 2012-11-22
KR20140078582A (ko) 2014-06-25
EP2709619B1 (en) 2017-10-11
US10206894B2 (en) 2019-02-19
EP2709619A2 (en) 2014-03-26
CN103957710A (zh) 2014-07-30
NZ618249A (en) 2016-03-31
US20190282521A1 (en) 2019-09-19
TW201247654A (en) 2012-12-01
CN103957710B (zh) 2016-04-20
KR102012164B1 (ko) 2019-08-20
US8802683B2 (en) 2014-08-12
US9457027B2 (en) 2016-10-04
MX2013013330A (es) 2014-07-09
US20170224640A1 (en) 2017-08-10
WO2012158672A2 (en) 2012-11-22
JP2014516033A (ja) 2014-07-07
WO2012158672A3 (en) 2014-05-08
RU2013155678A (ru) 2015-06-27
ZA201308541B (en) 2015-04-29
TWI520951B (zh) 2016-02-11
US9795575B2 (en) 2017-10-24
IL229381B (en) 2018-04-30
US10603294B2 (en) 2020-03-31
US20180064664A1 (en) 2018-03-08
US20160213668A1 (en) 2016-07-28
AU2012255935B2 (en) 2016-06-23
JP5833745B2 (ja) 2015-12-16
US9155738B2 (en) 2015-10-13
DK2709619T3 (en) 2018-01-15
US20140364364A1 (en) 2014-12-11
EP2709619A4 (en) 2015-04-22
CA2836099C (en) 2020-06-16

Similar Documents

Publication Publication Date Title
RU2606128C2 (ru) Соединения для применения в лечении мукозита
AU2012255935A1 (en) Compounds for use in treatment of mucositis
US20190084940A1 (en) Benzamide derivatives
CN105682655B (zh) 抗微生物化合物
EA037517B1 (ru) Антипролиферативные соединения и их фармацевтические композиции и применения
US20110178104A1 (en) Anti-Heparin Compounds
WO2019205687A1 (zh) 苯基联三氮唑类mll1-wdr5蛋白-蛋白相互作用抑制剂
AU2011334592C1 (en) Methods of treating eye diseases associated with inflammation and vascular proliferation
CA1328619C (en) Toxicity profiles in chemotherapy
JP2013530244A (ja) 免疫調節の方法
NZ618249B2 (en) Compounds for use in treatment of mucositis

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner